Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Interventional Treatment of Ovarian Cancer With Cancer Antigen-specific Engineered Immune Effector T Lymphocytes (OC-EIEs)

NCT03393962 is registered in ClinicalTrials.gov with Shenzhen Geno-Immune Medical Institute as lead sponsor.

NCT NCT03393962
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03393962 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Interventional Treatment of Ovarian Cancer With Cancer Antigen-specific Engineered Immune Effector T Lymphocytes (OC-EIEs)
Lead sponsor
Shenzhen Geno-Immune Medical Institute
Phase
Phase 1/2
Overall status
Enrolling by invitation
Start date
December 1, 2025
Completion date
December 31, 2028
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer